CYTOREDUCTIVE CHEMOTHERAPY WITH MITOXANTRONE, CYTOSINE ARABINOSIDE AND ETOPOSIDE FOLLOWED BY RECOMBINANT HUMAN G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
OBJECTIVES: I. Evaluate the efficacy of MCE (mitoxantrone/cytarabine/etoposide) followed by
granulocyte colony-stimulating factor to mobilize peripheral blood stem cells (PBSC) in
patients with chronic myeloid leukemia (CML). II. Evaluate the toxicity of this regimen.
III. Evaluate the cytoreductive effects of this regimen in CML as determined by the ability
to mobilize Philadelphia chromosome-negative PBSC. IV. Assess the time of peak CD34+ and
CD34+/CD38- cell concentrations in the peripheral blood of patients treated with this
OUTLINE: The following acronyms are used: ARA-C Cytarabine, NSC-63878 DHAD Mitoxantrone,
NSC-301739 G-CSF Granulocyte Colony-Stimulating Factor (source not specified) HU
Hydroxyurea, NSC-32065 MCE DHAD/ARA-C/VP-16 VP-16 Etoposide, NSC-141540 Single-Agent
Cytoreduction followed by 3-Drug Combination Chemotherapy/Stem Cell Mobilization. HU;
followed by MCE; G-CSF.
PROJECTED ACCRUAL: 30 patients will be entered over 3 years.
Primary Purpose: Treatment
Leona A. Holmberg, MD, PhD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|